This week, Joseph Walker and Peter Loftus for The Wally Street Journal highlight a new development in HIV prevention from Gilead: Yeztugo, a twice-yearly injectable drug that is 99.9% effective and only requires two shots a year, which solves two of HIV treatment’s longest-standing barriers, adherence and accessibility.
Kirsten Korosec for TechCrunch covers Lilly’s acquisition of Verve Therapeutics for up to $1.3bn to advance a one-time gene editing treatment that could permanently lower LDL cholesterol by ~50% and help to reduce cardiovascular disease, the world’s top killer, and which, despite its huge cost to the US economy, still lacks a cheap and simple treatment.
The US Senate has also passed a bill to create a regulatory framework for stablecoins, which requires them to be backed 1:1 by liquid assets and also mandates monthly reserve disclosures, in a watershed moment for the digital asset industry and a boon for crypto maximalists who have long campaigned for mainstream adoption.
